Antibodies from plants for bionanomaterials
Open Access
- 27 March 2017
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 9 (6)
Abstract
Antibodies are produced as part of the vertebrate adaptive immune response and are not naturally made by plants. However, antibody DNA sequences can be introduced into plants, and together with laboratory technologies that allow the design of antibodies recognizing any conceivable molecular structure, plants can be used as ‘green factories’ to produce any antibody at all. The advent of plant‐based transient expression systems in particular allows the rapid, convenient, and safe production of antibodies, ranging from laboratory‐scale expression to industrial‐scale manufacturing. The key features of plant‐based production include safety, speed, low cost, and convenience, allowing newcomers to rapidly master the technology and use it to its full advantage. Manufacturing in plants has recently achieved significant milestones and offers more than just an alternative to established microbial and mammalian cell platforms. The use of plants for product development in particular offers the power and flexibility to easily coexpress many different genes, allowing the plug‐and‐play construction of novel bionanomaterials, perfectly complementing existing approaches based on plant virus‐like particles. As well as producing single antibodies for applications in medicine, agriculture, and industry, plants can be used to produce antibody‐based supramolecular structures and scaffolds as a new generation of green bionanomaterials that promise a bright future based on clean and renewable nanotechnology applications. WIREs Nanomed Nanobiotechnol 2017, 9:e1462. doi: 10.1002/wnan.1462This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Biology-Inspired Nanomaterials > Protein and Virus-Based StructuresKeywords
Funding Information
- EU sixth framework project Pharma-Planta (LSHB-CT2003-503565)
- ERC advanced grant Future-Pharma (269110)
This publication has 174 references indexed in Scilit:
- Development of viral nanoparticles for efficient intracellular deliveryNanoscale, 2012
- GMP issues for recombinant plant-derived pharmaceutical proteinsBiotechnology Advances, 2012
- Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein AggregatesPharmaceutical Research, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodiesJournal of Virological Methods, 2009
- Protein Body Induction: A New Tool to Produce and Recover Recombinant Proteins in Plants2009
- Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticalsTransgenic Research, 2007
- Immunoabsorbent nanoparticles based on a tobamovirus displaying protein AProceedings of the National Academy of Sciences, 2006
- The production of recombinant pharmaceutical proteins in plantsNature Reviews Genetics, 2003
- Production of antibodies in transgenic plantsNature, 1989